Detalles de la búsqueda
1.
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
J Urol
; 209(5): 918-927, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36974724
2.
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
Prostate
; 82(11): 1107-1116, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35538298
3.
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Invest New Drugs
; 39(1): 182-192, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910338
4.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31563517
5.
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
Cancer
; 120(5): 761-7, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24375398
6.
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.
Cancer Epidemiol Biomarkers Prev
; 33(3): 419-425, 2024 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38189661
7.
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.
Cancer Res Commun
; 4(1): 55-64, 2024 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38108490
8.
Repetitively dosed docetaxel and ¹5³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Cancer
; 119(17): 3186-94, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23765638
9.
Targeting bone physiology for the treatment of metastatic prostate cancer.
Clin Adv Hematol Oncol
; 11(3): 134-43, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23598981
10.
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
J Immunother Precis Oncol
; 6(4): 162-169, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38143953
11.
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
J Immunother Cancer
; 11(3)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36948505
12.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
J Immunother Cancer
; 11(3)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36927527
13.
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Eur Urol
; 83(1): 29-38, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115772
14.
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Curr Treat Options Oncol
; 13(2): 174-88, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22528368
15.
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.
Clin Cancer Res
; 28(2): 318-326, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34667026
16.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
J Immunother Cancer
; 9(7)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301808
17.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer
; 9(7)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301809
18.
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Eur Urol Open Sci
; 34: 70-78, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34934969
19.
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
Clin Cancer Res
; 26(5): 984-989, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31601568
20.
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
Am Soc Clin Oncol Educ Book
; 40: 1-18, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32343604